AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked AstraZeneca PLC (NYSE: AZN ), Last week, Cambridge, U.K.-based AstraZeneca secured regulatory approval for a new breast cancer treatment while reporting strong Phase 3 trial data for its lung cancer